Scientists discovered a new way to protect memory in Alzheimer's by targeting the blood-brain barrier instead of amyloid ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Sanofi has agreed to acquire Vigil Neuroscience in a $470m deal, nearly a year after investing an initial $40m in the company ...

The US FDA has approved the first blood test to detect Alzheimer's disease in its early stages. This advancement promises ...

Researchers have found that the herpes virus, which causes cold sores, increases Alzheimer’s risk by as much as 80% by ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

A world-first brain scanning technique could identify signs of Alzheimer’s disease long before symptoms appear. The method, ...

EMA’s reluctance in approving drugs for the condition underscores Europe’s prioritisation of long-term safety over rapid ...

TREATING cold sores with anti-viral medicines could slash the risk of Alzheimer’s disease by 17 per cent, research suggests. Previous studies have found that the herpes simplex virus – ...

HSV-1 infection may be linked to the risk for Alzheimer’s disease, but antiviral treatment may be protective, a large ...

Trump’s executive order to cap U.S. costs risks limiting the supply of new pharmaceuticals. President Donald Trump’s ...